Monitor Nasdaq listing approval and the second closing of the Streeterville Capital equity facility, which is the key near-term catalyst for liquidity and going concern resolution. The direct listing price discovery process is novel and could produce significant volatility on the first trading day.
How similar events traded
Executive Summary
Med-X, Inc. filed Amendment No. 5 to its S-1 registration statement for a direct listing on Nasdaq. The company registers 16,248,842 post-split shares for resale by existing stockholders; the company will receive no proceeds. The filing updates the share count and reflects the Streeterville Capital equity facility amendment. The company has a history of net losses, an accumulated deficit of $57.8M as of September 30, 2026, and its auditor included a going concern explanatory paragraph for FY2025.
Key Financial Metrics
Key Facts
- Amendment No. 5 to S-1 for direct listing on Nasdaq under symbol MXRX
- Registers 16,248,842 post-split shares for resale by existing stockholders; company receives no proceeds
- Net loss of $10.0M for nine months ended September 30, 2026, vs $5.8M in prior year period
- Revenue of $1.65M for nine months ended September 30, 2026, up 19.7% YoY
- Accumulated deficit of $57.8M as of September 30, 2026
- Going concern opinion from auditor for FY2025; management believes listing and Streeterville funding alleviate doubt
- Streeterville Capital, LLC committed to purchase up to $30M of Series B Convertible Preferred Stock; $5M initial tranche at listing
- Chairman/CEO controls 54.3% voting power via Series A super voting preferred stock
- 1-for-2 reverse stock split to be implemented before listing
Financial Impact
Company has $989K cash, $470K working capital, and expects $4.625M net from Streeterville at listing to fund operations through November 2027
Risk Factors
- Nasdaq listing approval is not guaranteed; if denied, the offering terminates and Streeterville funding is unavailable
- Going concern risk persists if listing is delayed or Streeterville conditions are not met
- CEO controls 54.3% voting power, limiting other shareholder influence
- Streeterville convertible preferred could cause substantial dilution if stock price declines
- History of net losses and negative operating cash flow; revenue growth is slow relative to operating costs
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001477932-26-007188 |
| Document: medx_ex231.htm | 0001477932-26-007188 |
| Document: 0001477932-26-007188-index-headers.html | 0001477932-26-007188 |
| Document: 0001477932-26-007188-index.html | 0001477932-26-007188 |
| Document: 0001477932-26-007188.txt | 0001477932-26-007188 |
Track record
3 reports on MXRX
Filters
- Nov 19, 20262d ago S-1/A Neutral 5/10 Viewing Entry price pending
- Nov 17, 20264d ago S-1/A Neutral 5/10 No price data
- Nov 5, 202616d ago S-1/A Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers